Lexicon SVP awarded RSUs and stock options

Lexicon Pharmaceuticals insider compensation grant: SVP of Human Resources Wendy McDermott received equity awards on February 12, 2026.

Rhea-AI Filing Summary

Lexicon Pharmaceuticals insider compensation grant: SVP of Human Resources Wendy McDermott received equity awards on February 12, 2026. She acquired 250,200 restricted stock units, each representing a contingent right to one share of common stock, all held directly after the grant.

She was also granted stock options for 375,300 shares of common stock at an exercise price of $1.37 per share, also held directly. The restricted stock units vest in three equal installments each February 28 in the three years after the grant year, while the options vest 25% on the first anniversary of grant and then 1/48th per month with continued service.

Insider Trade Summary

Grant/Award: 625,500 shares

Grant/Award 2 txns

Insider McDermott Wendy

Role SVP, Human Resources

Type	Security	Shares	Price	Value
Grant/Award	Restricted Stock Units	250,200	$0.00	$0.00
Grant/Award	Stock Option (Right to Buy)	375,300	$0.00	$0.00

Holdings After Transaction: Restricted Stock Units — 250,200 contracts (Direct); Stock Option (Right to Buy) — 375,300 contracts (Direct)

Footnotes (3)

1. F1. Each restricted stock unit represents a contingent right to receive one share of common stock.
2. F2. Restricted stock units vest with respect to 1/3 of the shares subject to the restricted stock units on February 28 of each of the three years following the year of grant.
3. F3. Option vests with respect to 25% of the shares subject to the option on the first anniversary of grant, and vests 1/48th per month for each month of service thereafter.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did LXRX report for Wendy McDermott?

Lexicon Pharmaceuticals reported an equity grant to SVP Human Resources Wendy McDermott. On February 12, 2026, she received 250,200 restricted stock units and stock options for 375,300 shares, both held directly, as part of her compensation package.

How many restricted stock units did the LXRX executive receive?

The executive received 250,200 restricted stock units. Each restricted stock unit represents a contingent right to receive one share of Lexicon Pharmaceuticals common stock, subject to time-based vesting conditions tied to continued service with the company.

What are the vesting terms for the LXRX restricted stock units?

The restricted stock units vest in three equal installments. One-third of the 250,200 units vests on February 28 of each of the three years following the year of grant, provided the executive continues to provide service during that period.

What stock options were granted to the LXRX executive and at what price?

The executive was granted stock options covering 375,300 shares of common stock. These options have an exercise price of $1.37 per share, meaning she must pay $1.37 to purchase each underlying share when exercising the options.

How do the LXRX stock options vest over time?

The options vest based on continued service. Twenty-five percent of the 375,300 options vest on the first anniversary of the grant date, and the remaining options vest in equal monthly installments of 1/48th for each additional month of service.

Does the LXRX executive hold the awarded securities directly or indirectly?

The Form 4 indicates that both the restricted stock units and stock options are held directly. The ownership code is listed as “D,” and there is no footnote describing indirect ownership through a trust, family entity, or other intermediary.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/17/2026 - 04:10 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

McDermott Wendy

(Last) (First) (Middle)

2445 TECHNOLOGY FOREST BLVD.

11TH FLOOR

(Street)

THE WOODLANDS TX 77381

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
LEXICON PHARMACEUTICALS, INC. [ LXRX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	SVP, Human Resources

3. Date of Earliest Transaction (Month/Day/Year)
02/12/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	(1)	02/12/2026		A		250,200		(2)	(2)	Common Stock	250,200	$0	250,200	D
Stock Option (Right to Buy)	$1.37	02/12/2026		A		375,300		(3)	02/12/2036	Common Stock	375,300	$0	375,300	D

Explanation of Responses:

1. Each restricted stock unit represents a contingent right to receive one share of common stock.

2. Restricted stock units vest with respect to 1/3 of the shares subject to the restricted stock units on February 28 of each of the three years following the year of grant.

3. Option vests with respect to 25% of the shares subject to the option on the first anniversary of grant, and vests 1/48th per month for each month of service thereafter.

	/s/ Wendy E. McDermott	02/17/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.